HealthQuill Prostate cancer
Biogen Inc., a US biotechnology company, has got marketing authorisation from the European medicines regulator for its drug to treat neurodegenerative disease, amyotrophic lateral sclerosis.
Drugs Health Pharma

UK approves oral pill to treat advanced prostate cancer

HQ Team July 19, 2024: A new pill that treats hormone sensitive advance prostate cancer has been approved by the National Institute for.

Read More
Novartis AG will buy a US-based biotechnology company Mariana Oncology to expand its cancer portfolio for $1 billion.
Drugs Health Pharma

Novartis AG to buy Mariana Oncology for $1 billion to build RLT assets

HQ Team May 2, 2024: Novartis AG will buy a US-based biotechnology company Mariana Oncology to expand its cancer portfolio for $1 billion..

Read More
The jury is still out on which virus causes chronic fatigue syndrome, its diagnosis, the treatment options, and even its very terminology. Molecular biologists at the Cornell University revisited the syndrome, which is also known as myalgic encephalomyelitis (ME) and found it may be triggered by viral infections.
Drugs Health Medical

Nocturnal awakening and prostate cancer: What you need to know

Waking up in the middle of the night is called nocturnal awakening. Studies have found nearly 35% of people wake up in the.

Read More
A drug that mimics the benefits of rigorous exercise has been developed on mice by scientists at the University of Florida.
Drugs Health Medical

Boosting cardiorespiratory fitness lowers prostate cancer risk, study finds

HQ Team February 1, 2024: Cardio exercise can play a role in lowering the incidence of prostate cancer, according to new research. The.

Read More
The Food and Drug Administration (FDA) has green-lighted Astellas Pharma’s prostrate cancer drug Xtandi five weeks ahead of the scheduled approval date.
Drugs Health Pharma

Astellas’ prostate cancer drug for metastasis-free survival gets nod

HQ Team November 18, 2023: The Food and Drug Administration (FDA) has green-lighted Astellas Pharma’s prostrate cancer drug Xtandi five weeks ahead of.

Read More
The USFDA has approved Pfizer Inc’s oral Talzenna drug in combination with Xtandi to treat advanced prostate cancer in adult patients, according to a statement.
Drugs Health Pharma

Pfizer gets FDA nod for combination drug to treat advanced prostate cancer

HQ Team June 21, 2023: The USFDA has approved Pfizer Inc’s oral Talzenna drug in combination with Xtandi to treat advanced prostate cancer.

Read More
X